A PROCESS OF PREPARING PEGYLATED LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE

摘要

The delivery by liposome technology gives us the advantage to deliver toxic drugs to the target cells without causing damage to the normal cells. Also, many drugs with low aqueous solubility and/or combination of both water-soluble and lipid soluble drugs can be formulated in the liposomes, increasing the bioavailability of the drug, reducing dosage and also reducing systemic toxicity. Doxorubicin is a toxic antineoplastics agent used in the treatment of Metastatic ovarian cancer refractory to Paclitaxel and Platinum chemotherapy regimen and AIDS related Kaposi syndrome. It is available both in the normal and stealth liposomal injection form. Liposomal doxorubicin delivers the drug 5 to 11 times more to the sarcoma lesions, and also requires frequent dose modification, reduced toxicity to normal cells, reduced number to dosage administration and better patient compliance. The Pegylatation was carried out by Poly Ethylene Glycol (PEG). Pegylated Doxorubicin Liposomal Injection has a good chemical stability which is much better then the innovator's product in terms of physical and chemical stability as per the in-house specifications.